Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers
Authors:
- Vito LorussoVLVito Lorusso
- Gianpaolo PirovanoGPGianpaolo Pirovano
- Miles KirchinMKMiles Kirchin
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in Academic Radiology
- Vol. 6 (5) , 282-291
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat modelJournal of Magnetic Resonance Imaging, 1997
- Hepatic transport of gadobenate dimeglumine in TR− ratsAcademic Radiology, 1996
- Contrast-enhanced MR imagingClinical Radiology, 1996
- High-performance liquid chromatographic assay of the magnetic resonance imaging contrast agent gadobenate in plasma, urine and bileJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Binding of Gadobenate Dimeglumine to Proteins Extravasated into Interstitial Space Enhances Conspicuity of Reperfused InfarctsInvestigative Radiology, 1994
- Interim Results of Phase II Clinical Testing of Gadobenate DimeglumineInvestigative Radiology, 1994
- 3DFT-FISP MRI with Gadopentetate Dimeglumine in Differential Diagnosis of Small Liver TumorsJournal of Computer Assisted Tomography, 1994
- Soluble‐type hepatobiliary contrast agents for MR imagingJournal of Magnetic Resonance Imaging, 1993
- Abdominal imagingJournal of Magnetic Resonance Imaging, 1993
- Gd-BOPTA/Dimeg: Experimental disease imagingMagnetic Resonance in Medicine, 1991